| Product Unit Size | Cost | Quantity | Stock |
|---|
Nα,Nα-Dimethyl-L-arginine is also known as asymmetrical dimethyl-L-arginine (ADMA). This compound is an endogenous inhibitor of NOS and is involved in the regulation of the water/sodium balance. High levels of ADMA are associated with obesity, atherosclerosis, renal disease, and coronary artery disease. ADMA aggravates gastric mucosal lesions in vivo, increasing levels of TNF-α and suppressing gastric blood flow.
| Purity | ≥98% |
|---|---|
| Formula | C8H18N4O2 • NH3 |
| Formula Wt. | 219.28 |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Mauricio MD, Aldasoro M, Ortega J, et al. Endothelial dysfunction in morbid obesity. Curr Pharm Des. 2013;19(32):5718-29. PMID: 23448493.
Szlachcic A, Krzysiek-Maczka G, Pajdo R, et al. The impact of asymmetric dimethylarginine (ADAMA), the endogenous nitric oxide (NO) synthase inhibitor, to the pathogenesis of gastric mucosal damage. Curr Pharm Des. 2013;19(1):90-7. PMID: 22950506.
Twardowski ZJ. Sodium, hypertension, and an explanation of the "lag phenomenon" in hemodialysis patients. Hemodial Int. 2008 Oct;12(4):412-25. PMID: 19090863.
Surdacki A. L-arginine analogs--inactive markers or active agents in atherogenesis? Cardiovasc Hematol Agents Med Chem. 2008 Oct;6(4):302-11. PMID: 18855643.